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Functions of miRNAs in the 
Development, Diagnosis, and 
Treatment of Ovarian Carcinoma
Hulya Yazici
Abstract
miRNAs (miRNA) are small RNA molecules that are not to expressed to 
proteins. Their size is 20–22 nucleotides in length and they are highly conserved 
molecules among the species. miRNAs are synthesized in the nucleus as a primary 
miRNA. Primary miRNA is transferred to cytoplasm by Xpo5 protein (exportin-5) 
and then is processed by Dicer enzyme to a 22-nucleotide-sized long mature 
miRNA. miRNAs are differentially expressed in different diseases and are released 
into plasma by normal and tumor tissues during the cell metabolism. Ovarian 
carcinoma is the deadliest cancer among women. When the disease was diagnosed, 
the disease usually progressed. Currently, there is no biological marker to detect 
ovarian carcinoma at an early stage. Furthermore, there is a need for markers that 
are sensitive to chemotherapy changes and early detection of the disease. Because of 
this, miRNAs can be detected in plasma and can be used as highly significant bio-
logical markers and therapeutic targets for ovarian carcinoma. When the literature 
of the last 5 years is searched, there are many studies about miRNA and ovarian 
carcinoma. In this chapter, studies examining the relationship between ovarian car-
cinoma and miRNA from different angles are summarized under different sections.
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1. Introduction
Ovarian cancer (OC) is the sixth common cancer in women in the United States. 
According to GLOBOCAN data published in 2018, 295,414 new cases of ovarian 
cancer have been reported in the world. A total of 184,799 of these cases have been 
reported to have died due to ovarian carcinoma. The patients who died because 
of ovarian carcinoma had constituted 62.5% of the cases diagnosed in 2018 [1]. 
Ovarian carcinoma is diagnosed in women at peri- and postmenopausal status 
frequently [2].
Genetics, syndromes (breast and ovarian carcinoma syndrome and Lynch syn-
drome), family history, personal history of cancer or endometriosis, increasing age, 
reproductive history and infertility, hormone replacement therapy, and obesity are 
factors that may increase the risk of ovarian carcinoma. However, oral contracep-
tive usage, having pregnancy before age 26, breastfeeding, removal of the ovaries 
and fallopian tubes, hysterectomy, and tubal ligation are factors that may reduce the 
risk of ovarian carcinoma. Ovarian carcinoma comprises a heterogeneous group of 
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tumors with different histologic subtypes which have particular genetic structures 
and different response to treatment. The most common histological subtype is epi-
thelial ovarian carcinomas accounting for about 90% of cases and can be classified 
as serous, endometrioid, and clear-cell and mucinous carcinomas [3, 4].
However, a majority of women are diagnosed in an advanced stage because of 
the asymptomatic issue in the early stage and due to the lack of an adequate early 
detection screening method [5]. Ovarian cancer still remains as one of the lead-
ing causes of cancer-related deaths, and the treatments could be improved using 
predictive biomarkers to measure a response to ovarian cancer therapy. Currently, 
there is no available proven single biomarker in the clinical use for detecting ovarian 
carcinoma in the early stage with adequate sensitivity and specificity. To solve 
this problem, researchers have aimed at the identification and validation of novel 
biomarkers for the early detection of ovarian carcinoma using new technologies. 
Diagnostic markers for population screening would be a simple blood testing with 
95% specificity and sensitivity.
Similar to regulatory RNAs, microRNAs (miRNAs) are frequently deregulated 
in carcinogenesis. In ovarian tumorigenesis, numerous miRNAs were found altered, 
and some of these genes might represent ideal targets for diagnosis, prognosis, and 
treatment [6].
This chapter will focus on the recent advancements in miRNAs in the diagnosis, 
prognosis, and the treatments resistant to ovarian carcinoma.
2. Methods
PubMed search was performed using the keywords “ovarian carcinoma and 
miRNA” to prepare a comprehensive literature review. The results were filtered 
by published manuscripts in the last 5 years. A total of 193 associated papers, and 
review articles were found in the initial search. Additional searches were performed 
using the keywords genetic markers in ovarian cancer, multidrug resistance in 
ovarian cancer, and prognostic markers to supplement the information. 180 papers 
were selected for inclusion in the manuscript following the careful review of the 
abstracts. This chapter was written using the data of 3 meta-analyses, 20 reviews, 
and 67 original papers published in the last 5 years.
3. Biogenesis and functions of miRNAs
MicroRNAs (miRNAs) are a class of small noncoding RNA molecules which 
regulate gene expression at the posttranscriptional level [7, 8]. Thousands of 
miRNA sequences have been identified in a wide range of organisms after the 
discovery of small noncoding RNAs [9, 10] and have currently been shown to be 
highly conserved among a wide range of species [11]. The miRNA database contains 
38,589 entries representing hairpin precursor miRNAs, expressing 48,885 mature 
miRNA for 271 species (http://microrna.sanger.ac.uk). Each miRNA directly or 
indirectly regulates approximately 100 mRNA transcripts; however, a single gene 
coding protein could be regulated by more than one miRNA.
MicroRNAs are transcribed by RNA polymerase II or III, generating primary 
transcripts as short RNA hairpin structures (pre-miRNA) which are subsequently 
processed by cytoplasmic RNase III-type enzymes, Drosha and Dicer. The pro-
cessed, mature miRNA incorporates into the RNA-induced silencing protein 
complex (RISC) to regulate the function of genes through degradation of mRNA 
and inhibition of translation [12, 13]. RISC usually binds to the 3′-UTR region of 
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target mRNAs to repress translation. The degree of translation depends on the 
degree of complementarity between miRNA and target mRNA. miRNAs usually 
bind to specific sequences with partial complementarity on target RNA transcripts, 
called microRNA response elements (MREs), which result in translational repres-
sion in humans [14, 15].
MicroRNAs were shown to have a crucial function in oncogenesis by regulating 
cell proliferation, cell differentiation, and apoptosis as oncogenes or tumor sup-
pressors. The deregulation of miRNAs was suggested to be involved in a mechanism 
for cancer development. Also, miRNAs have been used as potential diagnostic or 
therapeutic targets in cancer treatment.
3.1  Important miRNAs as diagnostic and prognostic biomarkers and  
therapeutic targets in ovarian carcinoma
Ovarian carcinoma is the most lethal cancer among gynecological malignancies. 
Therefore, there is still a need for good diagnostic markers to detect the disease at an 
early stage and good prognostic markers to follow the effects of therapeutic agents 
during the chemotherapy of patients with ovarian carcinoma. Li et al. investigated 
the miR-193b expression level in the tissues of patients diagnosed with ovarian 
carcinoma and ovarian carcinoma cell lines. They found the aberrant expression 
level of miR-193b in the tissue of ovarian carcinoma patients. miR-193b showed 
decreased expression in tumor tissues of patients with ovarian carcinoma and was 
correlated with FIGO stage, histologic grade, ascites, lymph node metastasis, tumor 
size, and also poor survival. Therefore, they suggested that the level of miR193b 
expression could be a potential biomarker for ovarian carcinoma patients [16]. 
Fukagawa et al. investigated the expression level of miR-135a-3p in the serum of 
ovarian carcinoma patients compared to ovarian cysts and normal ovarian tissue 
and also analyzed the expression level of miR-135a-3p in ovarian carcinoma cell 
lines such as SKOV3, ES2, and xenograft under cisplatin and paclitaxel. According 
to their result, they suggested that the miR-135a-3p expression could be used as a 
noninvasive biomarker in serum of patients with ovarian carcinoma in the diag-
nosis and follow-up of the disease [17]. Zuberi et al. evaluated the impact of the 
miR-125b expression level in patients with ovarian carcinoma and found that the 
expression level of miR-125b was statistically significant and that it was increased 
in serum specimens of patients with ovarian carcinoma compared to the levels in 
serum specimens of the healthy controls. They also demonstrated that the upregu-
lation of miR-125b was associated with FIGO stage and lymph node involvement 
and distant metastasis and was correlated with hypermethylation of some tumor 
suppressor genes such as p16, p14, BRCA1, DAPK1, PTEN, and RASSF1A. Their 
results suggested that the expression level of mi-125b might be an early diagnostic 
biomarker to predict distant metastasis and lymph node status [18]. Zhang et al. 
investigated miR-613 expression in tissue of patients with ovarian carcinoma 
compared to matched normal adjacent tissue of patients. They found that low 
expression of miR-613 was associated with the FIGO stage, tumor grade, lymph 
node involvement, short progression-free survival (PFS), and overall survival (OS) 
in ovarian carcinoma patients. Their results indicated that miR-613 might be a good 
prognostic biomarker in patients with retinoblastoma [19]. Yanaihara et al. searched 
five miRNAs such as miR-132, miR-9, miR-126, miR-34a, and miR-21 in 12 high-
grade serous ovarian carcinoma and 15 clear-cell ovarian carcinoma patients. They 
found that five miRNAs showed statistically higher expression in patients with 
clear-cell ovarian carcinoma. They also investigated further biological significance 
of miR-9 expression especially and demonstrated that miR-9 might have distin-
guished histologic subtypes of ovarian carcinoma and might be used a therapeutic 
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target for treatment of ovarian carcinoma [20]. Yang et al. showed that miR-506 
was associated with poor prognosis in ovarian carcinoma (OC) patients [21]. Sun 
et al. demonstrated in their study that miR-506 expression was correlated with early 
FIGO stage and good and longer survival [22]. The results of both studies suggested 
that miR-506 might be used as a prognostic biomarker. Yuan et al. showed that 
miR-494 had an antitumor effect in the tissue of OC patients and that miR-494 
suppressed the cell proliferation and cell migration in epithelial ovarian carcinoma 
through the c-myc gene [23].
Agostini et al. studied 155 tissues of ovarian carcinoma including 30 sex cord-
stromal tumors, 22 borderline tumors, and 103 ovarian carcinomas and investigated 
the HMGA2 gene and its two miRNA targets in the study. They found that let-7a and 
miR-30c were highly decreased in all tumors in the study. Their results showed that 
Let-7a and miR30c were deregulated in OC patients, and the cause of deregulation 
in let-7a and miR30c might be due to the genomic imbalances, and the genomic 
imbalances resulted with the upregulation of HMGA2 gene. They suggested further 
research to better understand the associations between genetic imbalance and 
miRNA expression and prognostic and diagnostic importance in ovarian carcinoma 
[24]. Ma et al. investigated the expression level of miR-486-5p and its target, 
OLFM4 gene. Their results suggested that the decreased expression level of OLFM4 
was associated with higher-grade FIGO tumors and poor differentiation. OLFM4 is 
downregulated by miR-486-5p which contributed to the tumorigenesis of ovarian 
carcinoma, and the opposite might be possible. OLFM4 and miR-485-5p might be 
the therapeutic targets for ovarian carcinoma [25]. Teng et al. published an article 
explaining an association between DNMT3A/3B and miR-29b. The results showed 
that the downregulation of miR29b was controlled by high levels of DNMT3A/3B 
expression. The results were suggested that was a cross talk and feedback between 
DNMT3A/3B and miR-29b  and that the expression of miR-29b negatively con-
trolled DNMTs, especially DNMT3A/3B. The findings showed that miR-29b and 
inhibitors of DNMT3A/B might be therapeutic target for patients with ovarian 
carcinoma [26]. According to articles published by different authors, miR-199 was 
downregulated in epithelial ovarian carcinoma and targeted to c-Met, HIF1-alpha, 
HIF2-beta, and IKK-beta proteins. Therefore, c-Met and/or miR-199 might be a 
target for patients with metastatic ovarian carcinoma [27–29]. Although many stud-
ies have been conducted so far, there are many candidate molecules that can be used 
in the diagnosis and prognosis of ovarian cancer; however, most of them should be 
validated with larger patient groups.
3.2 miRNAs responsible for drug resistance in treatment of ovarian carcinoma
The response of a patient with ovarian cancer to chemotherapy is actually 
the most important factor determining the survival of the patient. The primary 
treatment for ovarian cancer is surgery. After surgery, the first-line treatment is 
platinum-based combination [cisplatin or carboplatin and/or taxane (paclitaxel)] 
[30]. The majority of patients, almost 70%, receive this treatment and show com-
plete remission. Patients were extremely sensitive to chemotherapy when they first 
received the treatment, and this situation changed during the next relapse period. 
The pharmacokinetics and pharmacodynamics of platinum-based therapies are 
known to be influenced by germ line genetic factors [31].
It is stated that many events associated with cisplatin resistance may be effective. 
It has been thought that these mechanisms can be generated by genetic and epigen-
etic alterations and miRNAs [32]. It is known that women with BRCA1 and BRCA2 
gene mutations had better response to chemotherapy and had longer survival. It was 
reported that the mechanism underlying situation was associated with miR-9 in 
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animal models. miR-9 downregulates the BRCA1 gene, causing the DNA repair 
mechanism not to function, and thus increases the sensitivity to chemotherapy. In 
a study by Sun et al., It was shown that miR-9 overexpression in 58 tumor tissue 
samples was associated with BRCA1 gene mutation. Accordingly, these patients 
have been reported to be extremely sensitive to chemotherapy, especially platinum-
based drugs and PARP inhibitors [33]. Furthermore, a similar relationship between 
BRCA1-miR-9 is present between the miR-93 and the PTEN gene. High miR-93 
and low PTEN expressions were investigated in ovarian carcinoma cell lines which 
were OVCAR3 and SKOV3 with and without platinum resistance. In this study by 
Fu et al., the relationship between PTEN-miR-93 was also shown in tumor tissues of 
10 ovarian cancer patients [34]. Let-7 expression has been reported to play a role in 
the response to chemotherapy. In particular, when paclitaxel was added to plati-
num regimen, it was shown that chemotherapy is beneficial in patients with low 
expression of let-7 [35]. It has been reported that high-level expression of miR622 is 
responsible for the development of resistance to platinum drugs and PARP inhibi-
tors in patients with high-grade serous ovarian cancer with BRCA1 mutation. It is 
emphasized that this effect of miR622 can be affected by correcting the disorders 
in the homologous recombination mechanism [36]. The blockade of PD-L1, PD-1, 
and CTLA-4, which are immune system inhibitor receptors, has been extremely 
successful in some advanced cancers. High expression of miR-424 (322), especially 
in tumors, prolongs progression-free survival in ovarian cancer patients. miR-424 
(322) blocks PD-L1 and CD80 expressions. The expression of miR424 (322) with 
PD-L1 immune checkpoint inhibitors is corrected, i.e., it is converted to normal. 
In in vivo and in vitro conditions, the restoration of miR424 (322), i.e., normaliza-
tion, eliminates the resistance to chemotherapy by activation of the T cell immune 
response via blocking PD-L1. There is a synergetic development of chemotherapy 
and immunotherapy. PD-L1 and chemoresistance are controlled via miRNAs [37]. 
In the literature, there are a number of studies showing the relationship between 
miRNAs and chemosensitivity and chemoresistance. Some miRNAs have a highly 
significant role in the use of combined therapies such as chemotherapy and immu-
notherapy. There is no doubt that the success of cancer treatments will increase as 
the relationship between miRNA molecules and cancer treatments is determined. 
However, there is no doubt that more studies should be done to use these molecules 
as standard in the clinic.
3.3  Important polymorphisms and mutations of miRNA processing and binding 
sites in ovarian carcinoma
3.3.1 3′UTR miRNA binding site of the KRAS gene
In 2008, Ratner et al. identified a germ line SNP in 3′UTR of the KRAS oncogene 
(rs61764370). The functional KRAS-variant was disrupted by the binding of let-7 
to 3′UTR region of KRAS gene [38]. In 2010, Ratner et al. reported that a single 
nucleotide polymorphism (SNP), rs61764370, located in the 3′UTR of the KRAS 
oncogene was associated with the risk of unselected epithelial ovarian cancer [39]. 
They also showed that the variant was associated with hereditary ovarian cancer 
patients carrying BRCA1 mutations and ovarian cancer patients with family history 
not carrying BRCA1 or BRCA2 [39]. This SNP was thought to be a strong candidate 
for cancer risk. These observations suggested that miRNAs can function as tumor 
suppressors or oncogenes [40]. An assay has subsequently been marketed to deter-
mine genotype at rs61764370 as a commercial test to determine the risk in women 
with a family history of ovarian cancer (http://www.miradx.com). However, in 
June 2011, Pharoah et al. showed in an extensive study with 8.669 unselected cases 
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of invasive epithelial ovarian cancer and 10.012 controls that the SNP was clinically 
useless for risk prediction in sporadic or familial ovarian cancer [41].
3.3.2 3′UTR miRNA binding site of the BRCA1 and BRCA2
BRCA1/2 mutations and targeted miRNAs to BRCA genes were demonstrated in 
many studies in the last decade [42] [43–45]. Moskwa et al. suggested that tumors 
overexpressing miRNAs such as miR-182 which target BRCA proteins can also be 
susceptible to PARP inhibition.
They suggested that the high level of miR-182 expression may affect BRCA1 
regulation for sporadic breast tumors. The changing level of miR-182 expression in 
different types of breast tumor cell lines affected the level of protein expression of 
BRCA1 and changed the sensitivity to PARP1 inhibition, both in breast cancer cell 
lines and in xenograft models [42]. Bioinformatic tools showed a binding site for 
miR-146a and miR-146b-5p in the upstream of BRCA1. This information suggested 
that BRCA1 gene can be downregulated by miR-146a and miR-146b-5p in basal-
like breast cancer cell lines and triple-negative breast tumors. This downregulation 
of BRCA1 increased a cell proliferation and a reduced homologous recombina-
tion repair rate controlled by BRCA1. Garcia et al. showed that the highest levels 
of miR-146a and/or miR-146b-5p were found in basal-like epithelial mammary 
tumor cell lines and breast tumors with triple-negative histology, and also the 
characteristics of these types of tumors are the closest tumors having carriers of 
BRCA1 mutations [43–45]. miRNAs are known to regulate tumor suppressor genes 
and oncogenes. The genetic alterations in the binding sites of miRNAs on DNA 
sequence of miRNA could affect the expression of tumor suppressor genes and 
oncogenes. Shen et al. searched the selected 17 miRNAs which have an important 
role in the development of breast cancer in 42 patients with familial breast carci-
noma. miR-30c-1 and miR-17 among 17 miRNAs were only observed in noncarriers 
of BRCA1/2 mutations. They showed that these two miRNAs, miR-30c-1 and miR-
17, resulted in conformational changes in their secondary structures and altered the 
expression in functional assays. They also showed that miR-17 could bind to the 
3′UTR of BRCA1 mRNAs. Their results suggested that functional genetic altera-
tions in miRNA genes can potentially alter the regulation of BRCA1 gene which is 
important for breast cancer [45]. The same perspective and scenario may be valid 
for patients with sporadic ovarian carcinoma having an overexpression of BRCA1, 
and the effect of PARP inhibitors can also be increased by eliminating BRCA 
expression via miR182 in ovarian carcinoma.
3.4  miRNAs as angiogenetic and metastatic biomarkers in  
ovarian carcinoma
The major challenge in treatment of ovarian carcinoma is the lack of good 
diagnostic and prognostic factors to follow and to diagnose in each stage of the 
disease. Li et al. established the study using SKOV3 and OVCAR3 ovarian carci-
noma cell lines. They demonstrated that miR-125a-5p, miR125b-5p, miR22-3p, 
miR205-5p, and miR-152 were significantly downregulated in SKOV3 cell lines 
and also showed the negative correlation between miR-152 and expression level 
of ERBB3. The findings of the study showed that miR-152 was associated with 
the regulation of the proliferation and metastasis of ovarian cancer cells via the 
repression of ERBB3 expression. miR-152 is an important molecule to suppress 
the proliferation, invasion, and migration of ovarian carcinoma cell lines. Their 
results suggested that miR-152 may be a potential therapeutic target for ovarian 
carcinoma [46].
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The interaction between HOTAIR and both miR-214 and miR-217 was shown 
in the study of Dong et al. on SKOV3 ovarian carcinoma cell line. Their results 
demonstrated that HOTAIR, which had an interaction with PIK3R3, regulated the 
proliferation, migration, and invasion in SKOV3 ovarian cell line via miR-214 and 
miR-217 [47].
Li et al. investigated miR-340 expression in five different ovarian carcinoma cell 
lines such as OVCAR3, CAOV3, HO-8910, ES-2, A2780, and FTE187. They showed 
that miR-340 was decreased in ovarian carcinoma cell lines and induced apoptosis 
in cells with downregulation of NF-ƘB1 to inhibit metastasis in ovarian carcinoma 
cell lines. They emphasized that miR-340-NF-ƘB1 interaction might be a potential 
therapeutic target or agent for patients with ovarian carcinoma [48].
Wang et al. examined the expression of MTA1 and miR-30c in ovarian cancer 
line, SKOV3, and normal human ovarian surface epithelial cell line, HOSE. They 
found that miR-30c expression was significantly reduced when MTA1 expression 
was higher and localized in the cytoplasm of the cells. Their results suggested that 
MTA1 and miR30c expression were altered in ovarian carcinoma cell line and might 
be associated in invasion and metastasis of patients with ovarian carcinoma [49].
3.5  Important miRNAs in exosomal and peripheral circulations in ovarian 
carcinoma
Numerous studies demonstrated the clinical importance of circulating miRNAs 
as diagnostic and prognostic biomarkers in all types of cancer. Circulating miRNAs 
in ovarian cancer were published in many studies using blood plasma, serum, 
ascites, and urine.
3.5.1 Exosomal miRNAs
The first study was published by Taylor et al. demonstrating that the levels 
of eight exosomal microRNAs extracted from sera which were miR-21, miR-141, 
miR-200a, miR-200c, miR-200b, miR-203, miR-205, and miR-214 were elevated at 
an advanced-stage ovarian carcinoma [50, 51]. The miRNA signature of exosomes 
showed that the circulating miRNAs can present the characteristics of the tumor.
3.5.2 miRNAs in sera
Many researchers investigated different miRNAs in the sera of OC patients 
[51–59].The microRNAs miR182, miR200a, miR200b, and miR200c from miR200 
family were investigated by Kan et al. in the sera of OC patients and healthy 
controls. They found significant differences between patients and controls and 
suggested that miR200b and miR200c had a power to discriminate serous ovarian 
cancer from healthy controls and had a potential as a biomarker of sera [53]. Chung 
et al. showed that the miR-132, miR-26a, miR-let7b, miR-145, and miR-143 were 
decreased in serum specimens of patients with ovarian carcinoma and healthy 
individuals [54]. Xu et al. showed significantly higher miR-21 levels in sera of 
patients with epithelial ovarian cancer than the levels in healthy controls. They 
also indicated the correlation between the increased miR-21 expression in sera and 
advanced FIGO stage, high tumor grade, and shortened overall survival. Their 
findings suggested that serum miR-21 may be a novel diagnostic and prognostic 
marker and could be used as a therapeutic target in advanced-stage ovarian car-
cinoma [55]. Hong et al. investigated the serum levels of miR-221 in patients with 
epithelial ovarian carcinoma and in controls. miR-221 was found to be upregulated 
in patients with EOC compared with the healthy controls. The expression level 
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of serum miR-221 was significantly associated with the International Federation 
of Gynecology and Obstetrics (FIGO) stage and tumor grade. In addition, higher 
serum miR-221 expression was shown to be an independent prognostic factor for 
epithelial ovarian carcinoma [56].
3.5.3 miRNAs in plasma
Some other scientists used plasma in investigating the circulating biomarkers for 
ovarian carcinoma [60–63]. Zheng et al. showed higher plasma miR-205 and lower 
let-7f expression in patients with ovarian carcinoma than in healthy controls. The 
joint use of both MiR-205 and let-7f provided higher diagnostic accuracy for epithelial 
ovarian carcinoma, especially in patients with stage I disease. They also demonstrated 
that the combination of these two miRNAs and carbohydrate antigen-125 (CA-125) 
further improved the accuracy of detection of epithelial carcinoma in plasma samples 
and that the elevated miR-483-5p expression was found in patients with ovarian 
carcinoma with stages III and IV compared with stages I and II. Moreover, they 
demonstrated that lower levels of let-7f was predictive for poor prognosis in patients 
with epithelial ovarian carcinoma. Their findings suggested that plasma miR-205 and 
let-7f can be biomarkers for ovarian cancer detection and prognosis [60]. Shapira 
et al. assessed the expression levels of 754 miRNAs in presurgical plasma samples 
of 42 women with serous epithelial ovarian cancer and 36 plasma samples collected 
from women who had a benign pelvic mass at surgery. There were six miRNAs, miR-
106b, miR-126, miR-150, miR-17, miR-20a, and miR-92a which were distinguished 
as benign in histology before surgery. They showed that 10 miRNAs in plasma can 
distinguish healthy controls from women with ovarian cancer and a benign neo-
plasm before surgery. In the comparison of healthy controls with patient’s plasma 
samples, they found that five miRNAs, miR-1274a, miR-30b, miR-30c, miR-625-3p, 
and miR720, were differentially expressed and also that the level of miR-139-5p, 
miR-142-3p, miR-484, miR-486, and miR-660 were higher in healthy controls when 
analyzed against patients having benign mass in their body. They demonstrated that 
MiR-720 and miR-20a were higher in women who died 2 years after their diagnosis, 
and women who survived 44 years after diagnosis had higher levels of miR-223,  
miR-126-3p, and miR-1290 in their plasma before surgery [62].
3.5.4 miRNAs in ascites
Vaksman et al. investigated the effusion supernatants in 86 patients with ovarian 
carcinoma. In the study, they demonstrated that there were significant associations 
between clinicopathologic parameters and the levels of miR-21, miR-23a, miR-23b, 
miR-29a, miR-99a, miR-125b, miR-200c, miR-320a, and miR-484 and also between 
miRNAs 21, 23b, and 29a and poor survival. It was shown that the higher expression 
of miR-21 in metastatic ovarian carcinoma constituted chemoresistance in ovarian 
carcinoma, and the higher expression of miR-23a and miR-29a was associated with 
significantly shorter PFS [64].
3.5.5 miRNAs in urine
Researchers detected miRNAs on the urine of patients with ovarian carcinoma 
in the studies in the literature [65, 66]. Zavesky et al. investigated the expression of 
miRNAs in the urine of patients with ovarian carcinoma and endometrial carci-
noma. They compared the expression levels of 18 miRNAs in OC patients before 
and after surgery. The expression levels of miR-92a, miR100, miR106b, and miR-
200b were found significantly different between patients with ovarian carcinoma 
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and healthy controls. The expression levels of miR100 and miR106b were lower; 
however, the expression levels of miR-92a and miR-200b were higher in patients 
with ovarian carcinoma compared with the levels in healthy controls [65]. Zhou 
et al. examined the urine specimen obtained from 39 OC patients, from 26 patients 
with benign gynecologic disease, and from 30 healthy controls. They found that 
miR30a-5p was upregulated in OC patients compared with the healthy controls, and 
they also showed that the level of miR30a-5p can be used to follow excess tissues of 
ovarian carcinoma after surgery [66].
3.6 Important miRNAs for autophagy in ovarian carcinoma
Some miRNAs participated in the control of autophagy by regulating ATGs 
proteins [67]. Yang et al. showed that the higher expression of mir-30d regulated 
autophagy through inhibiting LC3B-I conversion to LC3B-II enzymes and formation 
of autophagosome. Their results suggested that mir-30d disrupts the process of 
autophagy targeting multiple genes in the autophagy pathway. The data suggested 
that miR-30d might participate to oncogenesis and be used in the cancer therapy 
strategy [68]. Dai et al. investigated the expression levels of miR29b that targeted 
to genes of myeloid cell leukemia sequence 1 (MCL1), mitogen-activated protein 
kinase 10 (MAPK10), and autophagy-related protein 9A (ATG9A) and suggested 
that lower level of miR29b was an independent poor prognostic marker in ovarian 
carcinoma [69]. He et al. examined the downregulation of ATG14 through EGR1-
miR-152 in cisplatin resistance ovarian carcinoma cell lines of A2780, CP70, SKOV3, 
and DDP. They determined that miR-152 expression level was extremely low in the 
cisplatin-resistant cell lines. Therefore, they suggested that the overexpression of 
miR-152 might be a useful therapeutic strategy to overcome cisplatin resistance by 
inhibiting ATG14 expression in ovarian carcinoma [70].
3.7 Important miRNAs for invasion in ovarian carcinoma
Invasion into surrounding tissue is an important step of metastasis. Therefore, 
understanding the molecular mechanism of invasion may help to understand the 
metastasis process and identify novel biomarkers and therapeutic agents to treat and 
to protect patients against metastasis. Zhang et al. showed that there was a higher 
expression of miR-630 in 30 patients with ovarian carcinoma [71]. They also showed 
the effects of higher miR-360 expression in SKOV3 cell line. The results of the cell 
line study indicated that miR-630 targeted the KLF6 gene (Krüppel-like factor 6). 
KLF6 gene is responsible for cancer cell proliferation and migration. They demon-
strated that miR-630 supported the epithelial cancer proliferation and invasion via 
targeting KLF6 gene, and overexpression of miR-630 stimulated growth of ovarian 
carcinoma tumor in vivo. Therefore, miR-630 was suggested to be a possible thera-
peutic target in ovarian carcinoma [71]. Sun et al. determined that the expression of 
miR-548c decreased in ovarian and endometrium carcinoma. Their results suggested 
that miR548c affected the expression of Twist. Higher expression level of Twist was 
shown in ovarian and endometrium carcinoma. Therefore, they emphasized that 
miR-548c might be used for therapeutic purposes to impress the expression level of 
TWIST in overexpressing tumors such as ovarian and endometrium carcinoma [72]. 
Wei et al. examined miR-205 expression level in 30 patients with ovarian carcinoma 
and in 12 normal ovarian tissues, and they found miR-205 overexpression in ovar-
ian carcinoma tissue of patients. Also, the behavior of miR-205 was investigated in 
ovarian carcinoma cell lines of OVCAR5, OVCA8, and SKOV3. They determined 
that miR205 targeted to TCF21 gene (transcription factor 21) which significantly 
decreased in tumor tissue of OC patients [73]. They concluded that miR-205 was 
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associated with the invasive behavior of ovarian tumor cells by targeting and with 
the decrease of TCF21 expression. miR-205 and TCF21 were suggested to be used 
for anticancer purposes [73]. Human telomerase reverse transcriptase (hTERT) is 
another important molecule in ovarian carcinoma. Bai et al. investigated expres-
sion levels of miR-532 and miR-3064 and found that they were downregulated in 
60 tumor tissues of ovarian cancer patients, and there was an association between 
the decreased miR-532 and miR-3064 and poor survival of patients with ovarian 
carcinoma. Bai et al. also demonstrated that miR-532 and miR-3064 targeted to 
hTERT gene and inhibited the proliferation, epithelial-mesenchymal transitions 
(EMT), and invasion of ovarian carcinoma cells. Their results showed that miR-
3064 controlled the expression level of hTERT, and the role of miR-532 was limited 
in ovarian carcinoma. They suggested that both miR-532 and miR-3064 might be a 
good therapeutic agent for treatment of ovarian carcinoma [74].
3.8  An impact of miRNAs on epithelial-mesenchymal transitions (EMT) in 
ovarian carcinoma
3.8.1 miR-125a
The epithelial-to-mesenchymal transition (EMT) and its reversion, mesen-
chymal-to-epithelial transition (MET), are important mechanisms in carcinoma 
progression and tumor metastasis. The important regulators of this process are 
growth factors, transcription factors, and adhesion molecules in that the activity 
of microRNA (miRNA) is suggested to contribute to EMT, MET, and metastatic 
progression. In ovarian cancer cells, EMT induces by overexpression of EGFR which 
leads to transcriptional repression of the miR-125a. MiR125a is suggested to be a 
negative regulator of EMT. Therefore, the repression of miR-125a was suggested to be 
a potential novel therapeutic approach for invasive behavior of ovarian cancer [75].
3.8.2 miR-125b
miR-125b expression was lower in epithelial ovarian carcinoma. The expres-
sion of miR125b in ovarian carcinoma blocked the tumor invasion. The expression 
of miR125b was associated with EMT and also with the expression of SET gene. 
Functional studies showed that SET gene was a target for miR-125b. The downregu-
lated SET gene may be observed during tumor migration [76].
3.8.3 miR-200 family
Various studies on miR-200 family showed that the miR-200 family was 
associated with the inhibition of cancer metastasis via epithelial-to-mesenchymal 
transition. mRNAs of SMAD and ZEB gene families are the key targets for the 
inhibition of cancer cell metastasis stimulated by miR-200 via EMT. ZEB2 has 
specific sequences on its’ 3′ UTR region for miR-200a, miR-141, miR-200b, miR-
200c, 429, miR-200a, and miR-141. ZEB1 and ZEB2 are transcriptional repressor 
of E-Cadherin [77]. Wang et al. determined that the higher expressions of miR-429 
and miR-200 families in mesenchymal-like ovarian carcinoma cell lines elevated 
the MET and the sensitivity to cisplatin [78]. In addition, TET3 was a gene down-
regulated during the epithelial-mesenchymal transition (EMT) induced with 
TGF-β1 in ovarian carcinoma cell lines. miR-30d was associated as a downstream 
target of TET3 gene. miR-30d could not bind to the promoter of TET3 gene, and 
TGF-β1-associated EMT was stimulated owing to the demethylation on binding site 
of miR-30d [79].
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3.9 Important miRNAs on survival in ovarian carcinoma
Fu et al. found higher miR-222-3p expression level in tumors of OC patients. 
They determined that the overexpression of miR-222-3p was associated with good 
survival in patients with epithelial ovarian carcinoma. As a further research, they 
also investigated biological function of miR-222-3p in cell lines and in mouse mod-
els. The data of the in vitro experiments determined that miR-222-3p suppressed the 
cell proliferation and migration in ovarian cancer cell lines and downregulated AKT 
activation by decreased phosphorylation of AKT protein. They showed that GNAI2 
is a target for miR-222-3p and also induced PI3K/AKT pathway. They suggested that 
miR222-3p/GNAI2/AKT interactions might be used as a therapeutic target in ovarian 
carcinoma [80]. Zhou et al. showed that miR-595 is a significant biomarker to show 
poor prognosis in patients in ovarian carcinoma. They investigated miR-595 in 
tumors in epithelial ovarian carcinoma, and the lower expression of miR-595 was 
found associated with advanced FIGO stage and distant metastasis and short overall 
survival [81]. Shi et al. published a meta-analysis about miR-200 and miR-30. 
They showed that the expression levels of miR-200 family had significant associa-
tion with overall survival (OS) and insignificant association with progression-free 
survival (PFS) in general evaluation. They also evaluated their results in subgroup 
analysis and found that an increased expression level of miR-200a, miR-200c, 
and miR-141 was associated with better PFS for patients with ovarian carcinoma. 
A higher expression level of miR-30 was associated with good overall survival 
and progression-free survival [82]. Therefore, they suggested that both miR200 
family and miR-30 might be good prognostic biomarkers in patients with ovarian 
carcinoma. Kleeman et al. examined the prognostic and apoptotic potentials of 
miR-147b, miR-1912, and miR-3073a in ovarian carcinoma cell lines which have dif-
ferent genetic backgrounds such as SKOV3 (TP53 null), OVCAAR3 (TP53R248Q ), 
TOV21G, TOV112D (TP53R175H), A2780, and A2780cis (TP53K351N) with/without 
adding the chemotherapeutic agent of carboplatin. They showed that the expres-
sion level of miR-147b and miR-1912 was higher after carboplatin treatment in 
ovarian cancer cell lines, while the expression level of miR-147b and miR-1912 was 
lower in untreated ovarian cancer cell line with carboplatin. They underlined that 
these two-miRNA were leaded pro apoptotic signals and decreased the expression 
level of Bcl2 and affected to median survival of ovarian carcinoma cell lines [83]. 
Yoshioka et al. published that the expression level of WNT7A gene was higher in 300 
FFPE tissue of ovarian specimens including ovarian tumor, benign/borderline, and 
normal ovarian tissue. They used ovarian carcinoma cell lines and mouse models to 
characterize the role of WNT7A gene in ovarian tumor development and progres-
sion. They suggested that the re-expression of WNT7A gene could play an important 
role in malignant transformation of ovarian tissue and progression of ovarian 
carcinoma [84]. After the article was published by Yoshioka et al., MacLean et al. 
demonstrated that miR-15b expression targeted WNT7A gene and found an inverse 
association between WNT7A and miR-15b. Higher expression level of WNT7A 
gene and lower expression level of miR-15b were associated with poor survival in 
patients with ovarian carcinoma. Their data showed that WNT7A was controlled by 
miR-15b expression reduced by promoter methylation through the DNMT1 gene, a 
responsible methylation in the genome of ovarian carcinoma [85]. Sun et al. pub-
lished meta-analysis on miR-9 and its prognostic importance in ovarian carcinoma. 
Their results revealed that the decreased expression level of miR-9 was found to be 
associated with poor overall survival (OS) and PFS in patients with ovarian carci-
noma [86]. Wang et al. demonstrated that higher level expression of miR-532-5p was 
associated with the survival of patients with ovarian carcinoma in TCGA data and 
also ovarian carcinoma cell lines, such as SKOV3 and OVCAR3 [87].
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4. Conclusion remarks
Over the last 5 years, a large number of studies have been carried out to reveal 
the relationship between ovarian carcinoma and miRNAs. All of these studies about 
miRNA are promising for early detection of ovarian cancer, monitoring treatment, 
determining chemotherapy resistance, and discovering new therapeutic agents. 
With more extensive studies in the future and the use of effective miRNA molecules 
found in the clinic, ovarian cancer will be more manageable and early detectable. 
There is a need for a large number of well-selected patient groups and validated 
studies for miRNAs to be involved and used in the routine clinic practice. However, 
when all studies are completed, it is undoubted that miRNAs will contribute to 
cancer diagnosis, prognosis, and development of new chemotherapeutic drugs and 
beneficial to individualized medicine. It will be understood that the effects of these 
small molecules are actually greater than it is thought in the future.
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